NextCure enters ATM agreement for up to $14.5M common stock offering with H.C. Wainwright

NextCure, Inc.

ATM agreement allows sale of up to $14.5M of common stock at market prices, effective December 19, 2025.
Agent H.C. Wainwright receives 3.0% compensation on gross proceeds from shares sold.
Net proceeds to fund general corporate purposes, including preclinical studies and clinical trials.
Sales may be made on Nasdaq or in negotiated transactions; no minimum price or volume commitments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.